Pemirolast

Summary

Pemirolast (CHEMBL1201198) is an approved small molecule; indicated across 4 conditions including abdominal aortic aneurysm and asthma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 1
• Chemistry: 228.21 Da · C10H8N6O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201198
Name	Pemirolast
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	57697
Molecular formula	C10H8N6O
Molecular weight	228.21
InChIKey	HIANJWSAHKJQTH-UHFFFAOYSA-N

SMILES: CC1=CC=CN2C1=NC=C(C2=O)C3=NNN=N3

IUPAC name: 9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one

Also known as: Pemirolast, Pemirox, Permirolast, SID50112688, PEMIROLAST, PemirolastÊ, PemirolastÂ, Pemirolast (potassium), pemirolast

Parent form; salt/anhydrous children: CHEMBL1201050

Patent coverage: 2,040 distinct patent families (8,280 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
abdominal aortic aneurysm	2	MONDO:0005350	EFO:0004214
asthma	2	MONDO:0004979	MONDO:0004979
Duchenne muscular dystrophy	2	MONDO:0010679	MONDO:0010311

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03119714	PHASE2	TERMINATED	Pemirolast in Allergen Challenge (PEMAG)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).